Dr. Sager is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
181 Pleasant St
Newton, MA 02459Phone+1 844-724-3591Fax+1 844-724-3590
Summary
- Guiding cancer patients (adults and children alike) to access innovative therapies that maximize longevity and quality of life.
Education & Training
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2000 - 2003- Johns Hopkins UniversityResidency, Pediatrics, 1999 - 2000
Children's Hospital Los AngelesResidency, Pediatrics, 1997 - 1999
Weill Cornell MedicineClass of 1997
Clinical Trials
- Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer Start of enrollment: 2018 Sep 20
- Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma Start of enrollment: 2019 Jan 08
Publications & Presentations
PubMed
- 128 citationsA Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced MalignanciesD. Ross Camidge, Roy S. Herbst, Michael S. Gordon, S. Gail Eckhardt, Razelle Kurzrock
Clinical Cancer Research. 2010-02-15 - 21 citationsDiscodermolide analogues as the chemical component of combination bacteriolytic therapy.Amos B. Smith, B. Scott Freeze, Matthew J. LaMarche, Jason Sager, Kenneth W. Kinzler
Bioorganic & Medicinal Chemistry Letters. 2005-08-01 - 9 citationsIdentification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine–resistant cancer cellsKurtis E. Bachman, Jason Sager, Ian Cheong, Marco Catto, Alberto Bardelli
Molecular Cancer Therapeutics. 2005-06-01
Press Mentions
Ikena Oncology Appoints Dr. Sergio Santillana, MD, MSc, MBA as Chief Medical OfficerAugust 18th, 2020
Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR BlockadeAugust 12th, 2020
Kyn Therapeutics Strengthens Leadership Team with Key AppointmentsMay 7th, 2019
External Links
- Sagely Healthhttps://www.sagelyhealth.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
